Tubigon, Jesse .
HRN: 25-94-93 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/02/2024
CLINDAMYCIN 300MG (CAP)
10/02/2024
10/08/2024
ORAL
300 MG
Q6
INFECTED WOUND, LOWER LIP
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes